SAB Biotherapeutics (NASDAQ:SABS) Shares Down 6.6% – Here’s Why

SAB Biotherapeutics, Inc. (NASDAQ:SABS)’s share price was down 6.6% on Friday . The stock traded as low as $3.82 and last traded at $3.85. Approximately 274,534 shares traded hands during trading, a decline of 31% from the average daily volume of 396,190 shares. The stock had previously closed at $4.12.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Chardan Capital reissued a “buy” rating and issued a $12.00 price target on shares of SAB Biotherapeutics in a report on Thursday, December 18th. UBS Group started coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They set a “buy” rating and a $7.00 price objective on the stock. Wall Street Zen upgraded SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of SAB Biotherapeutics in a research report on Monday, December 29th. Finally, Guggenheim initiated coverage on shares of SAB Biotherapeutics in a research note on Friday, December 19th. They issued a “buy” rating and a $15.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

SAB Biotherapeutics Trading Down 6.6%

The firm’s fifty day moving average price is $3.96 and its 200-day moving average price is $3.11. The company has a market cap of $183.30 million, a price-to-earnings ratio of -1.25 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.49 and a quick ratio of 10.50.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.38. On average, equities analysts expect that SAB Biotherapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Vivo Capital LLC bought a new position in shares of SAB Biotherapeutics in the third quarter worth $22,954,000. Commodore Capital LP bought a new position in SAB Biotherapeutics in the 3rd quarter valued at about $8,847,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics during the 3rd quarter valued at about $8,847,000. Woodline Partners LP bought a new stake in shares of SAB Biotherapeutics during the 3rd quarter worth about $5,730,000. Finally, Propel Bio Management LLC acquired a new stake in shares of SAB Biotherapeutics in the 4th quarter worth approximately $2,442,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.